Patents by Inventor Junying Yuan

Junying Yuan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10710979
    Abstract: The present invention provides an EGFR kinase inhibitor and a preparation method and use thereof. Specifically, the present invention provides a compound as shown in formula (I), the definition of each group therein being as described in the description. Said compound is an efficient EGFR inhibitor.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: July 14, 2020
    Assignee: ZHEJIANG BOSSAN PHARMACEUTICAL CO. LTD.
    Inventors: Dawei Ma, Qiang Yu, Junying Yuan, Hongguang Xia, Dongpo Cai, Kailiang Wang, Chen Zhang, Shanghua Xia
  • Patent number: 10508102
    Abstract: A compound having the following structure (I): or a pharmaceutically acceptable salt, prodrug, stereoisomer or tautomer thereof, is provided. Related compounds, methods for preparation of the same and uses of the compounds for treatment of various indications, including treatment of necrotic cell diseases and/or inflammation, are also provided.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: December 17, 2019
    Assignees: President and Fellows of Harvard College, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
    Inventors: Junying Yuan, Yijun Zhou, Shan Qian, Dawei Ma
  • Publication number: 20190135718
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I)-(VIII) and by Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70). These necrostatins are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring necrostatins. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Application
    Filed: August 6, 2018
    Publication date: May 9, 2019
    Inventors: Junying Yuan, Emily P. Hsu
  • Publication number: 20190023690
    Abstract: A compound having the following structure (I): or a pharmaceutically acceptable salt, prodrug, stereoisomer or tautomer thereof, is provided. Related compounds, methods for preparation of the same and uses of the compounds for treatment of various indications, including treatment of necrotic cell diseases and/or inflammation, are also provided.
    Type: Application
    Filed: February 15, 2018
    Publication date: January 24, 2019
    Inventors: Junying Yuan, Yijun Zhou, Shan Qian, Dawei Ma
  • Publication number: 20180346444
    Abstract: The present invention provides an EGFR kinase inhibitor and a preparation method and use thereof. Specifically, the present invention provides a compound as shown in formula (I), the definition of each group therein being as described in the description. Said compound is an efficient EGFR inhibitor.
    Type: Application
    Filed: July 11, 2016
    Publication date: December 6, 2018
    Inventors: Dawei MA, Qiang YU, Junying YUAN, Hongguang XIA, Dongpo CAI, Kailiang WANG, Chen ZHANG, Shanghua XIA
  • Patent number: 9944628
    Abstract: A compound having the following structure (I): or a pharmaceutically acceptable salt, prodrug, stereoisomer or tautomer thereof, is provided. Related compounds, methods for preparation of the same and uses of the compounds for treatment of various indications, including treatment of necrotic cell diseases and/or inflammation, are also provided.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: April 17, 2018
    Assignees: President and Fellows of Harvard College, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
    Inventors: Junying Yuan, Yijun Zhou, Shan Qian, Dawei Ma
  • Publication number: 20170305824
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I)-(VIII) and by Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70). These necrostatins are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring necrostatins. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Application
    Filed: February 8, 2017
    Publication date: October 26, 2017
    Inventors: Junying Yuan, Emily P. Hsu
  • Patent number: 9725452
    Abstract: The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 8, 2017
    Assignees: Presidents and Fellows of Harvard College, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Tufts University, University of Houston
    Inventors: Junying Yuan, Alexei Degterev, Gregory D. Cuny
  • Patent number: 9643977
    Abstract: Described herein are compositions that inhibit the production of TNF? downstream of CD40 activation. As such, also described are various methods of using compositions exhibiting this activity for the treatment or prevention of inflammatory diseases associated with TNF? production or CD40 activation.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: May 9, 2017
    Assignee: President and Fellows of Harvard College
    Inventor: Junying Yuan
  • Patent number: 9586880
    Abstract: Compounds having the following structure (VI-A): or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, wherein RE1, RE2, RE3, RE4, ZE2 and ZE3 are as disclosed herein, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating disorders associated with necrosptosis are also provided.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: March 7, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Junying Yuan, Emily P. Hsu
  • Publication number: 20170050929
    Abstract: This invention pertains to screening methods for identifying autophagy inducing compounds.
    Type: Application
    Filed: August 26, 2016
    Publication date: February 23, 2017
    Inventors: Junying Yuan, Dawei Ma, Lihong Zhang
  • Patent number: 9499521
    Abstract: A compound having the following structure (I): or a pharmaceutically acceptable salt, prodrug, stereoisomer or tautomer thereof, is provided. Related compounds, methods for preparation of the same and uses of the compounds for treatment of various indications, including treatment of necrotic cell diseases and/or inflammation, are also provided.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: November 22, 2016
    Assignees: President and Fellows of Harvard College, Shanghai Institute of Organic Chemistry
    Inventors: Junying Yuan, Yijun Zhou, Shan Qian, Dawei Ma
  • Publication number: 20160304498
    Abstract: A compound having the following structure (I): or a pharmaceutically acceptable salt, prodrug, stereoisomer or tautomer thereof, is provided. Related compounds, methods for preparation of the same and uses of the compounds for treatment of various indications, including treatment of necrotic cell diseases and/or inflammation, are also provided.
    Type: Application
    Filed: June 27, 2016
    Publication date: October 20, 2016
    Inventors: Junying Yuan, Yijun Zhou, Shan Qian, Dawei Ma
  • Publication number: 20160194631
    Abstract: The present disclosure relates to methods for the modulation of autophagy and the treatment of autophgy-related diseases, including cancer, neurodegenerative diseases and pancreatitis.
    Type: Application
    Filed: August 6, 2015
    Publication date: July 7, 2016
    Inventors: Junying Yuan, Marta M. Lipinski
  • Publication number: 20160168128
    Abstract: A compound having the following structure (I): or a pharmaceutically acceptable salt, prodrug, stereoisomer or tautomer thereof, is provided. Related compounds, methods for preparation of the same and uses of the compounds for treatment of various indications, including treatment of necrotic cell diseases and/or inflammation, are also provided.
    Type: Application
    Filed: December 11, 2015
    Publication date: June 16, 2016
    Inventors: Junying YUAN, Yijun ZHOU, Shan QIAN, Dawei MA
  • Publication number: 20160102053
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Application
    Filed: July 10, 2015
    Publication date: April 14, 2016
    Inventors: Gregory D. CUNY, Xin TENG, Junying YUAN, Alexei DEGTEREV, John A. PORCO, JR.
  • Publication number: 20160024098
    Abstract: The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Inventors: Junying YUAN, Alexei DEGTEREV, Gregory D. CUNY
  • Patent number: 9108955
    Abstract: The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-?) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-? induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: August 18, 2015
    Assignees: President and Fellows of Harvard College, Tufts University, The Brigham and Women's Hospital, Inc., Trustees of Boston University
    Inventors: Gregory D. Cuny, Xin Teng, Junying Yuan, Alexei Degterev, John A. Porco, Jr.
  • Publication number: 20140323489
    Abstract: The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 30, 2014
    Applicants: President and Fellows of Harvard College, University of Houston, Tufts University, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciencess
    Inventors: Junying YUAN, Alexei DEGTEREV, Gregory D. CUNY
  • Patent number: 8741942
    Abstract: The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: June 3, 2014
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
    Inventors: Gregory D. Cuny, Prakash Jagtap, Junying Yuan, Alexei Degterev